UC Davis UC Davis Previously Published Works
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
(12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain Et Al
US 2012O190743A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain et al. (43) Pub. Date: Jul. 26, 2012 (54) COMPOUNDS FOR TREATING DISORDERS Publication Classification OR DISEASES ASSOCATED WITH (51) Int. Cl NEUROKININ 2 RECEPTORACTIVITY A6II 3L/23 (2006.01) (75) Inventors: Jerald Bain, Toronto (CA); Joel CD7C 69/30 (2006.01) Sadavoy, Toronto (CA); Hao Chen, 39t. ii; C Columbia, MD (US); Xiaoyu Shen, ( .01) Columbia, MD (US) A6IPI/00 (2006.01) s A6IP 29/00 (2006.01) (73) Assignee: UNITED PARAGON A6IP II/00 (2006.01) ASSOCIATES INC., Guelph, ON A6IPI3/10 (2006.01) (CA) A6IP 5/00 (2006.01) A6IP 25/00 (2006.01) (21) Appl. No.: 13/394,067 A6IP 25/30 (2006.01) A6IP5/00 (2006.01) (22) PCT Filed: Sep. 7, 2010 A6IP3/00 (2006.01) CI2N 5/071 (2010.01) (86). PCT No.: PCT/US 10/48OO6 CD7C 69/33 (2006.01) S371 (c)(1) (52) U.S. Cl. .......................... 514/552; 554/227; 435/375 (2), (4) Date: Apr. 12, 2012 (57) ABSTRACT Related U.S. Application Data Compounds, pharmaceutical compositions and methods of (60) Provisional application No. 61/240,014, filed on Sep. treating a disorder or disease associated with neurokinin 2 4, 2009. (NK) receptor activity. Patent Application Publication Jul. 26, 2012 Sheet 1 of 12 US 2012/O190743 A1 LU 1750 15OO 1250 OOO 750 500 250 O O 20 3O 40 min SampleName: EM2OO617 Patent Application Publication Jul. 26, 2012 Sheet 2 of 12 US 2012/O190743 A1 kixto CFUgan <tro CFUgan FIG.2 Patent Application Publication Jul. -
4695389.Pdf (3.200Mb)
Non-classical amine recognition evolved in a large clade of olfactory receptors The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Li, Qian, Yaw Tachie-Baffour, Zhikai Liu, Maude W Baldwin, Andrew C Kruse, and Stephen D Liberles. 2015. “Non-classical amine recognition evolved in a large clade of olfactory receptors.” eLife 4 (1): e10441. doi:10.7554/eLife.10441. http://dx.doi.org/10.7554/ eLife.10441. Published Version doi:10.7554/eLife.10441 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:23993622 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA RESEARCH ARTICLE Non-classical amine recognition evolved in a large clade of olfactory receptors Qian Li1, Yaw Tachie-Baffour1, Zhikai Liu1, Maude W Baldwin2, Andrew C Kruse3, Stephen D Liberles1* 1Department of Cell Biology, Harvard Medical School, Boston, United States; 2Department of Organismic and Evolutionary Biology, Museum of Comparative Zoology, Harvard University, Cambridge, United States; 3Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States Abstract Biogenic amines are important signaling molecules, and the structural basis for their recognition by G Protein-Coupled Receptors (GPCRs) is well understood. Amines are also potent odors, with some activating olfactory trace amine-associated receptors (TAARs). Here, we report that teleost TAARs evolved a new way to recognize amines in a non-classical orientation. -
(12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig. -
2D6 Substrates 2D6 Inhibitors 2D6 Inducers
Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride -
Haloperidol Versus Placebo for Schizophrenia
Haloperidol versus placebo for schizophrenia Item Type Article Authors Irving, Claire B.; Adams, Clive E. Citation Irving, C. B., Adams, C. E. & Lawrie, S. (2006). Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews, (4), pp.1-69. Download date 25/09/2021 21:20:50 Link to Item http://hdl.handle.net/20.500.12904/9860 Haloperidol versus placebo for schizophrenia (Review) Irving CB, Adams CE, Lawrie S This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2006, Issue 4 http://www.thecochranelibrary.com Haloperidol versus placebo for schizophrenia (Review) Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 3 METHODS ...................................... 3 RESULTS....................................... 6 DISCUSSION ..................................... 10 AUTHORS’CONCLUSIONS . 11 ACKNOWLEDGEMENTS . 11 REFERENCES ..................................... 12 CHARACTERISTICSOFSTUDIES . 25 DATAANDANALYSES. 67 Haloperidol versus placebo for schizophrenia (Review) i Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Review] Haloperidol versus placebo for schizophrenia Claire B Irving1, Clive E Adams1, Stephen Lawrie2 1Cochrane Schizophrenia -
Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany). -
Neurotransmitters-Drugs Andbrain Function.Pdf
Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Edited by R. A. Webster Department of Pharmacology, University College London, UK JOHN WILEY & SONS, LTD Chichester Á New York Á Weinheim Á Brisbane Á Singapore Á Toronto Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Copyright # 2001 by John Wiley & Sons Ltd. Bans Lane, Chichester, West Sussex PO19 1UD, UK National 01243 779777 International ++44) 1243 779777 e-mail +for orders and customer service enquiries): [email protected] Visit our Home Page on: http://www.wiley.co.uk or http://www.wiley.com All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P0LP,UK, without the permission in writing of the publisher. Other Wiley Editorial Oces John Wiley & Sons, Inc., 605 Third Avenue, New York, NY 10158-0012, USA WILEY-VCH Verlag GmbH, Pappelallee 3, D-69469 Weinheim, Germany John Wiley & Sons Australia, Ltd. -
(12) Patent Application Publication (10) Pub. No.: US 2010/0179214 A1 Dubé Et Al
US 20100179214A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0179214 A1 Dubé et al. (43) Pub. Date: Jul. 15, 2010 (54) DOXEPIN TRANS ISOMERS AND SOMERC continuation-in-part of application No. 1 1/804,720, MIXTURES AND METHODS OF USING THE filed on May 18, 2007. SAME TO TREAT SLEEP DSORDERS (60) Provisional application No. 60/898,378, filed on Jan. (75) Inventors: Susan E. Dubé, Carlsbad, CA (US); 30, 2007, provisional application No. 60/801,824, Neil B. Kavey, Chappaqua, NY filed on May 19, 2006, provisional application No. (US) 60/833,319, filed on Jul 25, 2006. Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP Publication Classification 2040 MAINSTREET, FOURTEENTH FLOOR (51) Int. Cl. IRVINE, CA 92.614 (US) A63L/335 (2006.01) A6IP 25/20 (2006.01) (73) Assignee: SOMAXON PHARMACEUTICALS, INC., (52) U.S. Cl. ........................................................ S14/450 San Diego, CA (US) (21) Appl. No.: 12/535,623 (57) ABSTRACT The invention relates to use of the trans-(E) isomer or iso (22) Filed: Aug. 4, 2009 meric mixtures containing specified ratios of the trans-(E) and cis-(Z) isomers of doxepin, metabolites of doxepin, phar Related U.S. Application Data maceutically-acceptable salts of doxepin and prodrugs of the (63) Continuation-in-part of application No. 12/022,788, same; compositions containing the same, for the treatment of filed on Jan. 30, 2008, now abandoned, which is a sleep disorders US 2010/0179214 A1 Jul. 15, 2010 DOXEPIN TRANS ISOMERS AND SOMERC brings scrutiny from the Drug Enforcement Administration MIXTURES AND METHODS OF USING THE and other regulatory bodies, and requires registration and SAME TO TREAT SLEEP DSORDERS administrative controls in physicians offices. -
Current Biological Treatments of Schizophrenia
Schizophrenia Block Adapted from the American Society for Clinical Psychopharmacology Model Curriculum * Learning Objectives • Identify major target symptoms of schizophrenia treatment • Become familiar with conventional & atypical antipsychotic medications • Recognize major side effects of antipsychotic medications • Recognize unique features of clozapine & depot antipsychotics Outline • Background about Schizophrenia • Dopamine Hypothesis • Dopamine Pathways • Efficacy of Anti-psychotics • Treats agitation • Prevents relapse • Compliance, Medication dose & relapse • Overview of an Antipsychotic Medication Trial • Different Anti-psychotic medications • Side effects of the Anti-psychotics • Common-EPS, TD, anti-cholinergic, metabolic syndrome, • Rare but serious-NMS • Antipsychotic selection and treatment strategies algorithm Dopamine Hypothesis of Schizophrenia Dopamine Hypothesis • Psychotic symptoms can be induced by dopamine agonists* • cocaine, amphetamines cause psychosis • All anti-psychotics are dopamine antagonists • Normal subjects-10% dopamine receptors occupied at baseline** • Schizophrenic subjects-20% dopamine receptors occupied at baseline** **Laruelle M, Quart J Nuc Med 1998;42:211 * Major Dopamine Pathways 1. Nigrostriatal tract- (extrapyramidal pathway) substantia nigra to caudate nucleus & putamen of the basal ganglia 2. Mesolimbic tract - midbrain tegmentum to nucleus accumbens & adjacent limbic structures 3. Mesocortical tract - midbrain tegmentum to anterior cortical areas 4. Tuberoinfundibular tract - arcuate & -
United States Patent (19) 11 Patent Number: 5,902,815 Olney Et Al
USOO5902815A United States Patent (19) 11 Patent Number: 5,902,815 Olney et al. (45) Date of Patent: May 11, 1999 54 USE OF 5HT2A SEROTONIN AGONISTS TO Hougaku, H. et al., “Therapeutic effect of lisuride maleate on PREVENT ADVERSE EFFECTS OF NMDA post-stroke depression” Nippon Ronen Igakkai ZaSShi 31: RECEPTOR HYPOFUNCTION 52-9 (1994) (abstract). Kehne, J.H. et al., “Preclinical Characterization of the Poten 75 Inventors: John W. Olney, Ladue; Nuri B. tial of the Putative Atypical Antipsychotic MDL 100,907 as Farber, University City, both of Mo. a Potent 5-HT2A Antagonist with a Favorable CNS Saftey Profile.” The Journal of Pharmacology and Experimental 73 Assignee: Washington University, St. Louis, Mo. Therapuetics 277: 968–981 (1996). Maurel-Remy, S. et al., “Blockade of phencyclidine-induced 21 Appl. No.: 08/709,222 hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors' European Jour 22 Filed: Sep. 3, 1996 nal of Pharmacology 280: R9–R11 (1995). 51) Int. Cl. ........................ A61K 31/445; A61K 31/54; Olney, J.W., et al., “NMDAantagonist neurotoxicity: Mecha A61K 31/135 nism and prevention,” Science 254: 1515–1518 (1991). 52 U.S. Cl. .......................... 514/285; 514/315; 514/318; Olney, J.W., et al., “Glutamate receptor dysfunction and 514/646 schizophrenia.” Arch. Gen. Psychiatry 52:998-1007 (1995). 58 Field of Search ............................. 514/285; 314/315, Pulvirenti, L. et al., “Dopamine receptor agonists, partial 314/318, 646 agonists and psychostimulant addiction' Trends Pharmacol Sci 15: 374-9 (1994). 56) References Cited Robles, R.G. et al., “Natriuretic Effects of Dopamine Agonist Drugs in Models of Reduced Renal Mass” Journal of U.S. -
Appendix 13C: Clinical Evidence Study Characteristics Tables
APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 .................................................................................................................... -
List of Vital Essential and Necessary Drugs and Medical Sundries For
LIST OF VITAL ESSENTIAL AND NECESSARY DRUGS AND 2015 MEDICAL SUNDRIES FOR PUBLIC HEALTH INSTITUTIONS Sixth Edition STANDARDS & REGULATION DIVISION JAMAICA List of Vital Essential and Necessary List of Drugs and Medical Sundries for Public Institutions List of Vital Essential and Necessary List of Drugs and Medical Sundries for Public Institutions CONTENTS CONTENTS Contd. Page Preface 5-6 Page Information on Hospitals and Health Centres 7 Explanatory Notes 8 Medical Sundries 69-73 Prescription Writing 9-10 Dental Supplies 74 Algorithm for Treatment of Hypertension 11-12 Radiotherapy – Diagnostic Agents 75 Algorithm for Management of Type 2 Diabetes 13-14 Raw Materials 76 List of Drugs Designated for NHF 15-17 List of Drugs Designated for JADEP 18 VOLUME11 – SPECIALIST LIST 77 VOLUME 1 – GENERAL LIST 19 CLASSIFICATION OF DRUGS SECTION 1. Cardiovascular System 78 CLASSIFICATION OF DRUGS SECTION 2. Central Nervous System 79 SECTION 1. Cardiovascular System 20-24 SECTION 3. Dermatology 80 SECTION 2. Central Nervous System 25-30 SECTION 4. Endocrine System 80 SECTION 3. Dermatology 31-33 SECTION 5. Gastro-intestinal System 81 SECTION 4. Ear, Nose and Oropharynx 34-35 SECTION 6. Infections 81 SECTION 5. Endocrine System 36-38 SECTION 7. Malignant Disease and SECTION 6. Gastro-intestinal System 39-40 Immunosuppression 82 SECTION 7. Infections 41-46 SECTION 8. Musculoskeletal and Joint Diseases 83 SECTION 8. Malignant Disease and SECTION 9. Ophthalmology 83 Immunosuppression 47-49 SECTION 10. Genito-Urinary Tract Disorders 84 SECTION 9. Musculoskeletal and Joint Diseases 50-51 SECTION 11. Respiratory System 84 SECTION 10. Nutrition and Blood 52-54 SECTION 12.